ES2819866T3 - Polipéptido ANGPTL8 y su uso para el tratamiento de condiciones asociadas con triglicéridos elevados - Google Patents

Polipéptido ANGPTL8 y su uso para el tratamiento de condiciones asociadas con triglicéridos elevados Download PDF

Info

Publication number
ES2819866T3
ES2819866T3 ES15848061T ES15848061T ES2819866T3 ES 2819866 T3 ES2819866 T3 ES 2819866T3 ES 15848061 T ES15848061 T ES 15848061T ES 15848061 T ES15848061 T ES 15848061T ES 2819866 T3 ES2819866 T3 ES 2819866T3
Authority
ES
Spain
Prior art keywords
polypeptide
angptl8
subject
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15848061T
Other languages
English (en)
Spanish (es)
Inventor
Zhonghao Liu
Xunshan Ding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NGM Biopharmaceuticals Inc
Original Assignee
NGM Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NGM Biopharmaceuticals Inc filed Critical NGM Biopharmaceuticals Inc
Application granted granted Critical
Publication of ES2819866T3 publication Critical patent/ES2819866T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
ES15848061T 2014-10-03 2015-10-02 Polipéptido ANGPTL8 y su uso para el tratamiento de condiciones asociadas con triglicéridos elevados Active ES2819866T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462059682P 2014-10-03 2014-10-03
PCT/US2015/053700 WO2016054494A1 (en) 2014-10-03 2015-10-02 Methods and compositions for treatment of conditions associated with elevated triglycerides

Publications (1)

Publication Number Publication Date
ES2819866T3 true ES2819866T3 (es) 2021-04-19

Family

ID=55631597

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15848061T Active ES2819866T3 (es) 2014-10-03 2015-10-02 Polipéptido ANGPTL8 y su uso para el tratamiento de condiciones asociadas con triglicéridos elevados

Country Status (7)

Country Link
US (3) US10071139B2 (enExample)
EP (2) EP3822287A1 (enExample)
JP (1) JP6680758B2 (enExample)
AU (1) AU2015327900B2 (enExample)
CA (1) CA2954082A1 (enExample)
ES (1) ES2819866T3 (enExample)
WO (1) WO2016054494A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015327900B2 (en) 2014-10-03 2020-04-30 Ngm Biopharmaceuticals, Inc. Methods and compositions for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
JP6843872B2 (ja) * 2016-02-04 2021-03-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 操作されたａｎｇｐｔｌ８遺伝子を有する非ヒト動物
WO2017151783A1 (en) 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
CA3019635A1 (en) * 2016-03-31 2017-10-05 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
HUE056878T2 (hu) * 2016-04-08 2022-03-28 Regeneron Pharma Hiperlipidémia kezelési módszerei ANGPTL8 inhibitorral és ANGPTL3 inhibitorral
CN110036029A (zh) 2016-11-17 2019-07-19 瑞泽恩制药公司 用抗angptl8抗体处理肥胖的方法
US10774139B2 (en) 2017-11-10 2020-09-15 Ngm Biopharmaceuticals, Inc. ANGPTL8-binding agents and methods of use thereof
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
CN110694068A (zh) * 2019-11-06 2020-01-17 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
CA2838824A1 (en) * 2011-06-10 2012-12-13 President And Fellows Of Harvard College Modulation of pancreatic beta cell proliferation
CN105073781A (zh) 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
ES2764833T3 (es) 2013-10-11 2020-06-04 The United States Of America Represented By The Sec Dep Of Health And Human Services Anticuerpos contra TEM8 y su uso
AU2015327900B2 (en) 2014-10-03 2020-04-30 Ngm Biopharmaceuticals, Inc. Methods and compositions for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CN110036029A (zh) 2016-11-17 2019-07-19 瑞泽恩制药公司 用抗angptl8抗体处理肥胖的方法
US10774139B2 (en) 2017-11-10 2020-09-15 Ngm Biopharmaceuticals, Inc. ANGPTL8-binding agents and methods of use thereof

Also Published As

Publication number Publication date
EP3201225B1 (en) 2020-08-19
AU2015327900B2 (en) 2020-04-30
US10071139B2 (en) 2018-09-11
US20210015902A1 (en) 2021-01-21
US20190060408A1 (en) 2019-02-28
CA2954082A1 (en) 2016-04-07
US20170143799A1 (en) 2017-05-25
EP3201225A1 (en) 2017-08-09
EP3201225A4 (en) 2018-05-23
WO2016054494A1 (en) 2016-04-07
JP2017531613A (ja) 2017-10-26
US10702587B2 (en) 2020-07-07
AU2015327900A1 (en) 2017-02-02
EP3822287A1 (en) 2021-05-19
JP6680758B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
ES2819866T3 (es) Polipéptido ANGPTL8 y su uso para el tratamiento de condiciones asociadas con triglicéridos elevados
US11358995B2 (en) Compositions and methods of use for treating metabolic disorders
ES2748038T3 (es) Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos
ES2690147T3 (es) Apelina pegilada y usos de la misma
ES2733220T3 (es) Proteína de fusión de hGH-XTEN y su uso en el tratamiento de la deficiencia de la hormona del crecimiento
JP2019056013A (ja) ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療
JP2017538395A (ja) 代謝障害を処置するための組成物及びその使用方法
ES2794082T3 (es) Uso de dímeros de IL-22 en la fabricación de medicamentos para tratar la pancreatitis
KR20230141958A (ko) 개선된 치료 지수를 위한 플라스민-내성 펩티드
JP2023116456A (ja) 強皮症関連血管障害を治療または改善するための組成物および方法
ES2463770T3 (es) Uso de la secuencia que codifica el dominio carboxilo terminal de la cadena pesada de la toxina tetánica como fármaco
US20150166629A1 (en) SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT
JP2008526875A (ja) 新規使用
US20040086515A1 (en) Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
CN118369351A (zh) Dsg2组合物和方法
BR112017005986B1 (pt) Complexo que compreende um primeiro heterodímero e um segundo heterodímero, composição farmacêutica e uso do complexo
BR112017001789B1 (pt) Polipeptídeos, dímero, método de produção dos mesmos, composição farmacêutica, uso dos mesmos e recipiente estéril para tratamento de distúrbios metabólicos
HK1237790B (en) Compositions and methods of use for treating metabolic disorders